MGNX — MACROGENICS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1125345 ·
Last close
$3.55
Market Cap
$226.14M
52W High
$5.08
52W Low
$1.29
ADV30
575,662
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 32,832,000 | — | -13,852,000 | 19,515,000 | 345,409,000 | 113,907,000 | 302,536,000 |
| Mar 2026 | 20,775,000 | 11,245,000 | -33,439,000 | -36,774,000 | 217,873,000 | 66,517,000 | 196,675,000 |
| Dec 2025 | 41,227,000 | 31,112,000 | -12,097,000 | -14,155,000 | 256,846,000 | 57,217,000 | 201,255,000 |
| Sep 2025 | 72,839,000 | 61,250,000 | 18,636,000 | 16,822,000 | 270,763,000 | 80,129,000 | 203,762,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-69,961,000
Investing CF
$-78,681,000
Financing CF
$69,589,000
CapEx
$-1,729,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.53
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,281,112,000
Inventory
$9,498,000
Receivables
$10,425,000
ST Investments
$87,712,000
EBIT TTM
$-57,725,000
Pretax Income TTM
$-71,030,000
Interest Exp TTM
$13,305,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$175,142,000
EBITDA
$-32,169,000
Free Cash Flow
$-69,411,128
Enterprise Value
$116,587,744
Total Cash
$173,304,992
Total Debt
$35,092,000
Shares Out
63,700,187
Trailing EPS
$-1.59
Book Value
$0.67
ROE
-225.8%
ROA
-8.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 149,500,000 | -72,841,000 | -74,620,000 | 256,846,000 | 201,255,000 | 55,591,000 | -81,040,000 |
| Dec 2024 | 149,962,000 | -110,578,000 | -66,966,000 | 261,655,000 | 145,598,000 | 116,057,000 | -68,373,000 |
| Dec 2023 | 58,749,000 | -168,244,000 | -9,058,000 | 298,418,000 | 145,805,000 | 152,613,000 | -78,205,000 |
| Dec 2022 | 150,018,000 | -121,418,000 | -119,758,000 | 280,468,000 | 138,455,000 | 142,013,000 | -86,959,000 |
TTM Snapshot
Revenues TTM
$157,083,000
NetIncome TTM
$-70,358,000
OpCashFlow TTM
—
Assets (Latest)
$217,873,000
Forward EPS
$-1.47
Max Pain — expiry 2026-10-16
max pain strike: $4.00 · spot: $3.73 · call oi: 2,730 · put oi: 804
Expected Move to 2026-10-16:
±$0.42
(11.24%) —
implied range
$3.31 –
$4.15
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AKBA | Akebia Therapeutics, Inc. | $225.79M | $0.81 | — |
| IFRX | InflaRx N.V. | $225.47M | $1.53 | — |
| GLSI | Greenwich LifeSciences, Inc. | $222.23M | $15.14 | — |
| SLGL | Sol-Gel Technologies Ltd. | $230.29M | $70.34 | — |
| KROS | Keros Therapeutics, Inc. | $230.79M | $11.64 | — |
News headlines (Yahoo Finance, 1h cache)
Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?
2026-10-09 12:40 · Yahoo
MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-09 20:05 · Yahoo
Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?
2026-08-15 00:50 · Yahoo
MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program
2026-08-11 20:05 · Yahoo
MacroGenics (MGNX) is a Great Momentum Stock: Should You Buy?
2026-07-02 16:00 · Yahoo
Bora Pharmaceuticals Completes Acquisition of MacroGenics' Rockville Manufacturing Operations
2026-07-02 15:00 · Yahoo
MacroGenics Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
2026-07-02 13:25 · Yahoo
MacroGenics to Receive Milestone Payment from Sanofi for Recent TZIELD® Approval
2026-06-22 20:43 · Yahoo
Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?
2026-09-23 13:40 · Yahoo
MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-13 22:50 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.